United Therapeutics (UTHR) Stock Analysis

November 11, 2026

This is a peer-relative look at United Therapeutics (UTHR): its performance, risk, profitability, growth, financial strength, dividend, and valuation are each measured against its Pharmaceuticals, Biotechnology & Life Sciences peers, so every number reads in context rather than in isolation.

Company Profile

Company profile fields for United Therapeutics (UTHR)
Profile Item	UTHR
Name	United Therapeutics Corporation
Country/Region	United States
GICS Sector	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology
GICS Sub-Industry	Biotechnology
Market Capitalization	23.94 billion USD
Currency	USD
Exchange	Nasdaq
Listing Date	June 17, 1999
Security Type	Common Stock

Price Performance

Cumulative Growth

UTHR

GSPC

United Therapeutics (UTHR) vs. S&P 500 (GSPC): Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for United Therapeutics (UTHR) and S&P 500 (GSPC). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for United Therapeutics (UTHR) and S&P 500 (GSPC). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

United Therapeutics (UTHR) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: UTHR	Industry group median
Total Return (1Y)	28.77%	24.62%
Total Return (3Y, Annualized)	37.63%	20.37%
Total Return (5Y, Annualized)	23.78%	-4.02%

Risk Profile

Drawdown History

UTHR

GSPC

United Therapeutics (UTHR) vs. S&P 500 (GSPC): Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for United Therapeutics (UTHR) and S&P 500 (GSPC). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

United Therapeutics (UTHR) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: UTHR	Industry group median
Volatility (1Y, Annualized)	35.00%	66.36%
Beta (5Y)	0.49	0.93
Max Drawdown (5Y)	-33.00%	-80.19%

Risk-Adjusted Performance

Risk-Return Positioning

Each dot is a stock plotted by 1-year volatility (risk) and 1-year return. UTHR is highlighted; the dashed line is the Capital Allocation Line from the risk-free rate through the industry median — dots above it are stronger on a risk-adjusted basis.

Risk-Adjusted Metrics

United Therapeutics (UTHR) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: UTHR	Industry group median
Sharpe Ratio (1Y)	0.70	0.36
Sortino Ratio (1Y)	1.29	0.58

Profitability

ROE (TTM)

United Therapeutics (UTHR) posts ROE of 19.13%, in the upper peer quartile. That suggests the company earns more from each dollar of shareholders’ equity than most industry peers, a useful capital-efficiency signal.

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.13%

Group distribution

Max: 109.18%
UTHR: 19.13%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Largest peers

LLY: 86.02%
NVS: 24.33%
AZN: 22.57%
JNJ: 20.02%
UTHR: 19.13%
MRK: 5.06%
ABBV: --

Where United Therapeutics (UTHR) stands on ROE within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Net Margin (TTM)

United Therapeutics (UTHR) keeps 38.61% of revenue as net profit on net margin, above the industry benchmark range. That is unusually strong bottom-line conversion, though tax effects, asset sales, or other one-off gains should be checked before treating it as durable.

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.61%

Group distribution

UTHR: 38.61%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Largest peers

UTHR: 38.61%
LLY: 31.90%
AZN: 17.68%
NVS: 17.49%
JNJ: 16.20%
ABBV: 15.67%
MRK: 3.64%

Where United Therapeutics (UTHR) stands on net margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Operating Margin (TTM)

United Therapeutics (UTHR) turns 28.99% of revenue into operating profit, putting operating margin in the upper peer quartile. Before financing and taxes enter the picture, the day-to-day business keeps more of each sales dollar than most industry peers.

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

28.99%

Group distribution

Max: 83.12%
UTHR: 28.99%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Largest peers

LLY: 53.66%
ABBV: 39.59%
MRK: 35.22%
NVS: 34.27%
AZN: 29.57%
UTHR: 28.99%
JNJ: 25.74%

Where United Therapeutics (UTHR) stands on operating margin within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Profitability Metrics

United Therapeutics (UTHR) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: UTHR	Industry group median
ROE (TTM)	19.13%	-26.66%
ROA (TTM)	10.91%	-12.50%
Net Margin (TTM)	38.61%	0.00%
Operating Margin (TTM)	28.99%	0.00%
Gross Margin (TTM)	86.34%	37.87%

Growth

Revenue Growth

United Therapeutics (UTHR) grew revenue 10.61%, roughly around the peer group's normal range. Top-line momentum looks broadly typical for the industry.

United Therapeutics (UTHR): Revenue Growth across different time periods, set against Pharmaceuticals, Biotechnology & Life Sciences industry-group medians.

EPS Growth

United Therapeutics (UTHR) grew earnings per share 13.07%, roughly around the peer group's normal range. Bottom-line momentum looks broadly typical for the industry.

United Therapeutics (UTHR): EPS Growth across different time periods, set against Pharmaceuticals, Biotechnology & Life Sciences industry-group medians.

Growth Metrics

United Therapeutics (UTHR) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: UTHR	Industry group median
Revenue Growth (YoY)	10.61%	11.45%
Revenue Growth (3Y CAGR)	18.02%	9.94%
EPS Growth (YoY)	13.07%	4.28%
EPS Growth (3Y CAGR)	22.92%	4.17%

Financial Strength

Current Ratio (MRQ)

United Therapeutics (UTHR) has current ratio of 4.61, in the healthier middle range for its industry. The short-term asset cushion looks balanced relative to peers rather than stretched thin.

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.61

Group distribution

Max: 25.13
Q3: 12.13
Median: 5.52
UTHR: 4.61
Q1: 2.47
Min: 0.10

Largest peers

UTHR: 4.61
LLY: 1.39
MRK: 1.35
JNJ: 1.02
AZN: 1.01
NVS: 0.88
ABBV: 0.87

Where United Therapeutics (UTHR) stands on current ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Debt / Equity (MRQ)

No usable debt-to-equity ratio is available for United Therapeutics (UTHR) this period, so the balance-sheet leverage read is skipped.

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

Group distribution

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00
UTHR: --

Largest peers

NVS: 1.29
LLY: 1.23
MRK: 1.20
AZN: 0.66
JNJ: 0.55
UTHR: --
ABBV: --

United Therapeutics (UTHR) doesn’t report debt-to-equity ratio this period; the box shows the Pharmaceuticals, Biotechnology & Life Sciences group’s distribution and the dots its largest members.

Financial Strength Metrics

United Therapeutics (UTHR) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: UTHR	Industry group median
Current Ratio (MRQ)	4.61	5.52
Debt / Equity (MRQ)	--	0.15
Net Debt / EBITDA	-1.53	1.08

Dividends

Dividend Yield (TTM)

United Therapeutics (UTHR) pays no dividend, leaving dividend yield at 0.00% this period. Shareholders may still receive value through reinvestment or buybacks, but there is no dividend income to compare here.

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Group distribution

UTHR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Largest peers

NVS: 2.88%
ABBV: 2.40%
MRK: 2.29%
JNJ: 1.94%
AZN: 1.73%
LLY: 0.49%
UTHR: 0.00%

Where United Therapeutics (UTHR) stands on dividend yield within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Payout Ratio (TTM)

United Therapeutics (UTHR) paid no earnings out as dividends this period, leaving payout ratio at 0.00%. There is no dividend payout to size against earnings.

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

Group distribution

UTHR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Largest peers

MRK: 343.43%
ABBV: 117.35%
NVS: 90.46%
JNJ: 80.12%
AZN: 45.38%
LLY: 21.71%
UTHR: 0.00%

Where United Therapeutics (UTHR) stands on payout ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Dividend Metrics

United Therapeutics (UTHR) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: UTHR	Industry group median
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

United Therapeutics (UTHR) trades at P/E ratio of 21.22, near the industry’s usual earnings multiple. The stock is not showing a clear peer discount or premium on trailing earnings.

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

21.22

Group distribution

Max: 85.34
Q3: 43.46
Median: 26.69
UTHR: 21.22
Q1: 13.30
Min: 0.07

Largest peers

MRK: 148.21
ABBV: 50.05
LLY: 43.95
JNJ: 41.92
NVS: 31.02
AZN: 26.37
UTHR: 21.22

Where United Therapeutics (UTHR) stands on P/E ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

P/S Ratio (TTM)

United Therapeutics (UTHR) trades at 7.51 on P/S ratio, roughly in the peer group’s normal range. The market is not making a strong cheap-or-rich statement about its revenue base.

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.51

Group distribution

Max: 58.18
Q3: 25.77
UTHR: 7.51
Median: 7.30
Q1: 3.01
Min: 0.01

Largest peers

LLY: 13.95
ABBV: 7.80
UTHR: 7.51
JNJ: 6.69
MRK: 5.37
NVS: 5.35
AZN: 4.63

Where United Therapeutics (UTHR) stands on P/S ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

P/B Ratio (MRQ)

United Therapeutics (UTHR) trades at 3.80 on P/B ratio, roughly in line with the industry’s normal price-to-book range. Its balance sheet is not being priced at a clear discount or premium versus peers.

UTHR

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.80

Group distribution

Max: 13.53
Q3: 6.54
UTHR: 3.80
Median: 3.25
Q1: 1.69
Min: -5.59

Largest peers

LLY: 29.96
NVS: 8.25
JNJ: 8.16
MRK: 8.06
AZN: 5.59
UTHR: 3.80
ABBV: -112.34

Where United Therapeutics (UTHR) stands on P/B ratio within its Pharmaceuticals, Biotechnology & Life Sciences peer group — the box is the group’s distribution and the dots its largest members.

Valuation Metrics

United Therapeutics (UTHR) metric values compared with Pharmaceuticals, Biotechnology & Life Sciences industry-group medians
Metric	Current stock: UTHR	Industry group median
P/E Ratio (TTM)	21.22	26.69
P/S Ratio (TTM)	7.51	7.30
P/B Ratio (MRQ)	3.80	3.25
Free Cash Flow Yield (TTM)	1.90%	-1.66%